Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

Clinical trials for MET inhibitors have demonstrated limited success for their use in colon cancer (CC). However, clinical efficacy may be obscured by a lack of standardisation in MET assessment for patient stratification. In this study, we aimed to determine the molecular context in which MET is de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephanie G. Craig, Svenja Mende, Matthew P. Humphries, Victoria Bingham, Amélie Viratham Pulsawatdi, Maurice B. Loughrey, Helen G. Coleman, Stephen McQuaid, Richard H. Wilson, Sandra Van Schaeybroeck, Jacqueline A. James, Manuel Salto‐Tellez
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	c‐MET IHC protein colon cancer MET amplification MET R970C mutation MET RNA‐ISH MET T992I mutation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0b8be54a07784f57bd958f3c8b5f5b03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

Ejemplares similares